HK1251159A1 - 改善的納米顆粒遞送系統 - Google Patents

改善的納米顆粒遞送系統

Info

Publication number
HK1251159A1
HK1251159A1 HK18110619.0A HK18110619A HK1251159A1 HK 1251159 A1 HK1251159 A1 HK 1251159A1 HK 18110619 A HK18110619 A HK 18110619A HK 1251159 A1 HK1251159 A1 HK 1251159A1
Authority
HK
Hong Kong
Prior art keywords
delivery systems
nanoparticle delivery
improved nanoparticle
improved
systems
Prior art date
Application number
HK18110619.0A
Other languages
English (en)
Inventor
Leon Wan
Winnie Lui
Paul Tardi
Lawrence Mayer
Original Assignee
Celator Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Celator Pharmaceuticals Inc filed Critical Celator Pharmaceuticals Inc
Publication of HK1251159A1 publication Critical patent/HK1251159A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5192Processes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/337Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/41641,3-Diazoles
    • A61K31/41841,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/554Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being a steroid plant sterol, glycyrrhetic acid, enoxolone or bile acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5146Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153Polyesters, e.g. poly(lactide-co-glycolide)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Botany (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK18110619.0A 2015-07-15 2018-08-17 改善的納米顆粒遞送系統 HK1251159A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562192973P 2015-07-15 2015-07-15
US201562252396P 2015-11-06 2015-11-06
PCT/US2016/042330 WO2017011685A1 (en) 2015-07-15 2016-07-14 Improved nanoparticle delivery systems

Publications (1)

Publication Number Publication Date
HK1251159A1 true HK1251159A1 (zh) 2019-01-25

Family

ID=57757767

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18110619.0A HK1251159A1 (zh) 2015-07-15 2018-08-17 改善的納米顆粒遞送系統

Country Status (17)

Country Link
US (3) US10285951B2 (zh)
EP (1) EP3322404A4 (zh)
JP (2) JP2018521068A (zh)
KR (1) KR20180029242A (zh)
CN (1) CN107920985B (zh)
AU (2) AU2016294617B2 (zh)
BR (1) BR112018000217A2 (zh)
CA (1) CA2991062C (zh)
CO (1) CO2018000146A2 (zh)
HK (1) HK1251159A1 (zh)
IL (1) IL256797B (zh)
MA (1) MA42458A (zh)
MX (1) MX2018000611A (zh)
RU (1) RU2018105494A (zh)
SG (1) SG10201912394VA (zh)
WO (1) WO2017011685A1 (zh)
ZA (1) ZA201800130B (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3082831A1 (en) * 2017-11-20 2019-05-23 Icahn School Of Medicine At Mount Sinai Inhibiting trained immunity with a therapeutic nanobiologic composition
US20210023017A1 (en) * 2018-03-16 2021-01-28 University Of Massachusetts Yeast cell wall particle encapsulation of biodegradable pro-payloads
KR102088663B1 (ko) * 2018-03-20 2020-03-13 한국세라믹기술원 친수성 및 소수성 약물의 동시 전달을 위한 온도민감성 나노스펀지 플랫폼 및 이의 용도
WO2020123481A1 (en) * 2018-12-10 2020-06-18 Celator Pharmaceuticals Inc. Combination formulations of taxanes and mtor inhibitors
AU2020329923A1 (en) * 2019-08-13 2022-02-24 Peptinovo Biopharma Inc. Palm for the treatment of Chemotherapy-Induced Peripheral Neuropathy incidental to the treatment of cancer
AU2022239614A1 (en) 2021-03-19 2023-10-12 Icahn School Of Medicine At Mount Sinai Compounds for regulating trained immunity, and their methods of use

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003028696A2 (en) 2001-10-03 2003-04-10 Celator Technologies Inc. Compositions for delivery of drug combinations
JP2005518354A (ja) * 2001-11-19 2005-06-23 コントロール・デリバリー・システムズ・インコーポレイテッド コドラッグを含有する医薬組成物
CA2514500A1 (en) * 2003-02-20 2004-09-10 University Of Connecticut Health Center Methods for using compositions comprising heat shock proteins or alpha-2-macroglobulin in the treatment of cancer and infectious disease
EP1786443B1 (en) 2004-07-19 2018-06-06 Celator Pharmaceuticals, Inc. Particulate constructs for release of active agents
AU2006235538A1 (en) * 2005-04-12 2006-10-19 Wisconsin Alumni Research Foundation Micelle composition of polymer and passenger drug
CN101878024B (zh) * 2007-11-28 2014-04-09 塞拉特药物股份有限公司 改良的紫杉烷递送***
BRPI1014854A2 (pt) * 2009-03-30 2016-05-03 Cerulean Pharma Inc "conjugados polímero-agente, partículas, composições, e métodos de uso relacionados"
EP2499486A4 (en) 2009-11-13 2013-11-27 Infinity Pharmaceuticals Inc COMPOSITIONS, KITS, AND METHODS FOR IDENTIFICATION, EVALUATION, PREVENTION, AND THERAPY OF CANCER
US20120052097A1 (en) * 2010-08-20 2012-03-01 Cerulean Pharma Inc. Therapeutic peptide-polymer conjugates, particles, compositions, and related methods
BR112013012485A2 (pt) * 2010-11-19 2016-09-06 Glaxosmithkline Ip No 2 Ltd método de tratamento com inibidor braf
WO2012149405A2 (en) * 2011-04-29 2012-11-01 Selecta Biosciences, Inc. Tolerogenic synthetic nanocarriers for regulating innate immune responses
US20140308363A1 (en) * 2011-05-31 2014-10-16 Bind Therapeutics, Inc. Drug loaded polymeric nanoparticles and methods of making and using same
DE102011109374A1 (de) * 2011-08-04 2013-02-07 Bock 1 Gmbh & Co. Kg Stuhl mit Wippmechanik
CA2953371C (en) * 2014-06-30 2021-08-24 Tarveda Therapeutics, Inc. Targeted conjugates and particles and formulations thereof

Also Published As

Publication number Publication date
CN107920985A (zh) 2018-04-17
JP2018521068A (ja) 2018-08-02
IL256797A (en) 2018-06-28
MX2018000611A (es) 2018-09-06
SG10201912394VA (en) 2020-02-27
US20180207104A1 (en) 2018-07-26
EP3322404A4 (en) 2019-03-20
US20190209484A1 (en) 2019-07-11
KR20180029242A (ko) 2018-03-20
BR112018000217A2 (pt) 2018-09-04
US11413253B2 (en) 2022-08-16
CA2991062C (en) 2023-06-20
JP2022033751A (ja) 2022-03-02
AU2016294617A1 (en) 2018-01-25
ZA201800130B (en) 2018-12-19
CA2991062A1 (en) 2017-01-19
AU2016294617B2 (en) 2021-09-16
RU2018105494A3 (zh) 2019-12-17
US10285951B2 (en) 2019-05-14
RU2018105494A (ru) 2019-08-15
AU2021286353A1 (en) 2022-01-20
US20210052508A1 (en) 2021-02-25
CO2018000146A2 (es) 2018-04-19
CN107920985B (zh) 2022-03-01
WO2017011685A1 (en) 2017-01-19
MA42458A (fr) 2018-05-23
EP3322404A1 (en) 2018-05-23
IL256797B (en) 2021-05-31

Similar Documents

Publication Publication Date Title
HK1252464B (zh) 氣霧劑輸送系統
GB201802837D0 (en) Awrosol delivery system
EP3725349C0 (en) IMPROVED MEDICINE DISTRIBUTION SYSTEMS
EP3212173A4 (en) Delivery systems
HK1249034A1 (zh) 遞送媒介物
ZA201502203B (en) Nano particulate delivery system
EP3283752C0 (en) FLUID SUPPLY SYSTEM
HK1251159A1 (zh) 改善的納米顆粒遞送系統
HK1250370A1 (zh) 基於硼替佐米的遞送系統
GB201407614D0 (en) Content delivery system
GB201600229D0 (en) Fluid delivery system
GB201703170D0 (en) Improved goods delivery systems
GB201600232D0 (en) Fluid delivery system
GB201715590D0 (en) Delivery system
GB2559712B (en) Solid state delivery system
GB201420903D0 (en) Fluids delivery system
IL246874A0 (en) drug delivery system
IL247106B (en) Material delivery system
GB201509934D0 (en) Nanoparticles
GB201517654D0 (en) Object delivery system
GB201614126D0 (en) Delivery vehicle
GB2532245B (en) Cardioplegic agent delivery system
GB201721699D0 (en) Delivery system
GB201712561D0 (en) Delivery system
GB201522636D0 (en) Delivery system